Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myelome (IFM)

被引：0
|
作者：
Touzeau, Cyrille
Leleu, Xavier P.
Mariette, Clara
Manier, Salomon
Brechignac, Sabine
Vincent, Laure
Hebraud, Benjamin
Decaux, Olivier
Schulmann, Samantha
Lenoir, Caroline
Godmer, Pascal
Farge, Agathe
Saint Paul, Laure Peyro
Parienti, Jean-Jacques
Macro, Margaret
机构：
[1] Univ Hosp Nantes, Nantes, France
[2] Ctr Hosp Univ Poitiers, Poitiers, France
[3] CHU Grenoble, Grenoble, France
[4] Lille Univ Hosp, Lille, France
[5] APHP Hop Avicenne, Bobigny, France
[6] Montpellier Univ Hosp, Montpellier, France
[7] Canc Univ, Inst Toulouse Oncopole, Toulouse, France
[8] Univ Hosp, Rennes, France
[9] CHU Nancy, Nancy, France
[10] Polyclin Bordeaux Nord Nord Acquitaine, Bordeaux, France
[11] GHBA, Vannes, France
[12] CHU, IHBN, Caen, France
[13] CHU, Caen, France
[14] CHU Caen, Caen, France
[15] Univ Caen Hosp Ctr, Caen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8054
引用
收藏
页数：1
相关论文
共 19 条
  • [1] Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail RRMM patients: A multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myelome (IFM).
    Leleu, Xavier
    Macro, Margaret
    Touzeau, Cyrille
    Mariette, Clara
    Manier, Salomon
    Brechignac, Sabine
    Vincent, Laure
    Hebraud, Benjamin
    Decaux, Olivier
    Schulmann, Samantha
    Lenoir, Caroline
    Godmer, Pascal
    Farge, Agathe
    Saint Paul, Laure Peyro
    Parienti, Jean-Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du Myelome (IFM)
    Macro, Magaret
    Touzeau, Cyrille
    Mariette, Clara
    Manier, Salomon
    Brechignac, Sabine
    Vincent, Laure
    Hebraud, Benjamin
    Decaux, Olivier
    Schulmann, Samantha
    Lenoir, Caroline Bureau
    Godmer, Pascal
    Parienti, Jean-Jacques
    Leleu, Xavier
    BLOOD, 2021, 138
  • [3] Bendamustine, bortezomib, and dexamethasone (BVD) in elderly patients with relapsed/refractory multiple myeloma (RRMM): The Intergroupe Francophone du Myelome (IFM) 2009-01 protocol.
    Rodon, Philippe
    Hulin, Cyrille
    Pegourie, Brigitte
    Tiab, Mourad
    Anglaret, Bruno
    Benboubker, Lotfi
    Jardel, Henry
    Decaux, Olivier
    Kolb, Brigitte
    Roussel, Murielle
    Garderet, Laurent
    Leleu, Xavier
    Fitoussi, Olivier
    Chaleteix, Carine
    Casassus, Philippe
    Lenain, Pascal
    Moreau, Philippe
    Petillon, Marie-Odile
    Mathiot, Claire
    Avet-Loiseau, Herve
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myelome (IFM)
    Perrot, Aurore
    Lauwers-Cances, Valerie
    Touzeau, Cyrille
    Decaux, Olivier
    Hulin, Cyrille
    Macro, Magaret
    Stoppa, Anne-Marie
    Chretien, Marie Lorraine
    Karlin, Lionel
    Mariette, Clara
    Jacquet, Caroline
    Roussel, Murielle
    Guillemot, Coralie
    Devlamynck, Laure
    Avet-Loiseau, Herve
    Moreau, Philippe
    Attal, Michel
    BLOOD, 2021, 138
  • [5] Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial
    Rodon, Philippe
    Hulin, Cyrille
    Pegourie, Brigitte
    Tiab, Mourad
    Anglaret, Bruno
    Benboubker, Lotfi
    Jardel, Henry
    Decaux, Olivier
    Kolb, Brigitte
    Roussel, Murielle
    Garderet, Laurent
    Leleu, Xavier
    Fitoussi, Olivier
    Chaleteix, Carine
    Casassus, Philippe
    Lenain, Pascal
    Moreau, Philippe
    Petillon, Marie Odile
    Mathiot, Claire
    Avet-Loiseau, Herve
    BLOOD, 2012, 120 (21)
  • [6] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
    Moreau, Philippe
    Hulin, Cyrille
    Caillot, Denis
    Marit, Gerald
    Perrot, Aurore
    Garderet, Laurent
    Facon, Thierry
    Benboubker, Lotfi
    Karlin, Lionel
    Tiab, Mourad
    Arnulf, Bertrand
    Fermand, Jean-Paul
    Leleu, Xavier
    Touzeau, Cyrille
    Roussel, Murielle
    Planche, Lucie
    Minvielle, Stephane
    Bene, Marie-Christine
    Avet-Loiseau, Herve
    Dejoie, Thomas
    Attal, Michel
    BLOOD, 2016, 128 (22)
  • [7] Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation ( ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyeLome (IFM)
    Moreau, Philippe
    Hulin, Cyrille
    Caillot, Denis
    Marit, Gerald
    Perrot, Aurore
    Garderet, Laurent
    Facon, Thierry
    Benboubker, Lofti
    Karlin, Lionel
    Tiab, Mourad
    Arnulf, Bertrand
    Leleu, Xavier
    Touzeau, Cyrille
    Roussel, Murielle
    Planche, Lucie
    Avet-Loiseau, Herve
    Dejoie, Thomas
    Attal, Michel
    BLOOD, 2017, 130
  • [8] All Oral Triplet Iberdomide Ixazomib and Dexamethasone in Elderly Patients With Multiple Myeloma Patients at First Relapse: Results of the IFM Phase 2 Study I2D
    Touzeau, Cyrille
    Leleu, Xavier
    Tiab, Mourad
    Macro, Margaret
    Perrot, Aurore
    Gay, Julie
    Chateleix, Carine
    Roussel, Murielle
    Karlin, Lionel
    Jacquet, Caroline
    Manier, Salomon
    Hulin, Cyrille
    Decaux, Olivier
    Richez, Valentine
    Chalopin, Thomas
    Mohty, Mohamad
    Orsini-Piocelle, Frederique
    Caillot, Denis
    Sonntag, Cecile
    Avet-Loiseau, Herve
    Planche, Lucie
    Corre, Jill
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S38 - S39
  • [9] Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)
    Roussel, Murielle
    Hebraud, Benjamin
    Hulin, Cyrille
    Leleu, Xavier
    Facon, Thierry
    Boyle, Eileen
    Touzeau, Cyrille
    Pegourie, Brigitte
    Perrot, Aurore
    Stoppa, Anne-Marie
    Marolleau, Jean-Pierre
    Moreau, Philippe
    Avet-Loiseau, Herve
    Devlamynck, Laure
    Lauwers-Cances, Valerie
    Attal, Michel
    BLOOD, 2019, 134
  • [10] Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
    Roussel, Murielle
    Moreau, Philippe
    Huynh, Anne
    Mary, Jean-Yves
    Danho, Clotaire
    Caillot, Denis
    Hulin, Cyrille
    Fruchart, Christophe
    Marit, Gerald
    Pegourie, Brigitte
    Lenain, Pascal
    Araujo, Carla
    Kolb, Brigitte
    Randriamalala, Edouard
    Royer, Bruno
    Stoppa, Anne-Marie
    Dib, Mammoun
    Dorvaux, Veronique
    Garderet, Laurent
    Mathiot, Claire
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    Attal, Michel
    BLOOD, 2010, 115 (01) : 32 - 37
12